288 related articles for article (PubMed ID: 25949526)
1. The clinical potential of ramosetron in the treatment of irritable bowel syndrome with diarrhea (IBS-D).
Min YW; Rhee PL
Therap Adv Gastroenterol; 2015 May; 8(3):136-42. PubMed ID: 25949526
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of 5-hydroxytryptamine 3 receptor antagonists in irritable bowel syndrome: A systematic review and meta-analysis of randomized controlled trials.
Zheng Y; Yu T; Tang Y; Xiong W; Shen X; Jiang L; Lin L
PLoS One; 2017; 12(3):e0172846. PubMed ID: 28291778
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine.
Lee KJ; Kim NY; Kwon JK; Huh KC; Lee OY; Lee JS; Choi SC; Sohn CI; Myung SJ; Park HJ; Choi MK; Bak YT; Rhee PL
Neurogastroenterol Motil; 2011 Dec; 23(12):1098-104. PubMed ID: 21920001
[TBL] [Abstract][Full Text] [Related]
4. Ramosetron Reduces Symptoms of Irritable Bowel Syndrome With Diarrhea and Improves Quality of Life in Women.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Akiho H; Nakashima Y; Nishida A; Haruma K
Gastroenterology; 2016 Feb; 150(2):358-66.e8. PubMed ID: 26551550
[TBL] [Abstract][Full Text] [Related]
5. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials.
Qi Q; Zhang Y; Chen F; Zuo X; Li Y
BMC Gastroenterol; 2018 Jan; 18(1):5. PubMed ID: 29310568
[TBL] [Abstract][Full Text] [Related]
6. Effect of ramosetron on stool consistency in male patients with irritable bowel syndrome with diarrhea.
Fukudo S; Ida M; Akiho H; Nakashima Y; Matsueda K
Clin Gastroenterol Hepatol; 2014 Jun; 12(6):953-9.e4. PubMed ID: 24315882
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Serotonin Type 3 Receptor Antagonist Ramosetron on Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)-Like Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Trial.
Tomita T; Fukui H; Morishita D; Mori S; Oshima T; Shinzaki S; Miwa H
J Clin Med; 2022 Nov; 11(23):. PubMed ID: 36498457
[TBL] [Abstract][Full Text] [Related]
8. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome.
Chiba T; Yamamoto K; Sato S; Suzuki K
Clin Exp Gastroenterol; 2013; 6():123-8. PubMed ID: 23922505
[TBL] [Abstract][Full Text] [Related]
9. Optimal dose of ramosetron in female patients with irritable bowel syndrome with diarrhea: A randomized, placebo-controlled phase II study.
Fukudo S; Matsueda K; Haruma K; Ida M; Hayase H; Akiho H; Nakashima Y; Hongo M
Neurogastroenterol Motil; 2017 Jun; 29(6):. PubMed ID: 28205278
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of alosetron for the treatment of irritable bowel syndrome in women and men: a meta-analysis of eight randomized, placebo-controlled, 12-week trials.
Rahimi R; Nikfar S; Abdollahi M
Clin Ther; 2008 May; 30(5):884-901. PubMed ID: 18555935
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the irritable bowel syndrome severity index in Japanese male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():7. PubMed ID: 28293280
[TBL] [Abstract][Full Text] [Related]
12. Effect of ramosetron on conditioned emotional stress-induced colonic dysfunction as a model of irritable bowel syndrome in rats.
Funatsu T; Takeuchi A; Hirata T; Keto Y; Akuzawa S; Sasamata M
Eur J Pharmacol; 2007 Nov; 573(1-3):190-5. PubMed ID: 17658508
[TBL] [Abstract][Full Text] [Related]
13. Effect of ramosetron in female patients with irritable bowel syndrome with diarrhea: a phase III long-term study.
Fukudo S; Kinoshita Y; Okumura T; Ida M; Hayashi K; Akiho H; Nakashima Y; Haruma K
J Gastroenterol; 2016 Sep; 51(9):874-82. PubMed ID: 26800997
[TBL] [Abstract][Full Text] [Related]
14. Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials.
Andresen V; Montori VM; Keller J; West CP; Layer P; Camilleri M
Clin Gastroenterol Hepatol; 2008 May; 6(5):545-55. PubMed ID: 18242143
[TBL] [Abstract][Full Text] [Related]
15. Optimizing outcomes with alosetron hydrochloride in severe diarrhea-predominant irritable bowel syndrome.
Lucak SL
Therap Adv Gastroenterol; 2010 May; 3(3):165-72. PubMed ID: 21180598
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome.
Matsueda K; Harasawa S; Hongo M; Hiwatashi N; Sasaki D
Digestion; 2008; 77(3-4):225-35. PubMed ID: 18667823
[TBL] [Abstract][Full Text] [Related]
17. Randomized, placebo-controlled, phase IV pilot study of ramosetron to evaluate the co-primary end points in male patients with irritable bowel syndrome with diarrhea.
Ida M; Nishida A; Akiho H; Nakashima Y; Matsueda K; Fukudo S
Biopsychosoc Med; 2017; 11():8. PubMed ID: 28331539
[TBL] [Abstract][Full Text] [Related]
18. Cilansetron: a new serotonergic agent for the irritable bowel syndrome with diarrhoea.
Chey WD; Cash BD
Expert Opin Investig Drugs; 2005 Feb; 14(2):185-93. PubMed ID: 15757394
[TBL] [Abstract][Full Text] [Related]
19. [Antagonists of the type 3 serotonin receptor (5 -HT3) in IBS].
Komoto S; Miura S
Nihon Rinsho; 2006 Aug; 64(8):1487-90. PubMed ID: 16898618
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome.
Hirata T; Keto Y; Funatsu T; Akuzawa S; Sasamata M
J Pharmacol Sci; 2007 Jul; 104(3):263-73. PubMed ID: 17652911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
